Suppr超能文献

放射性碘难治性甲状腺癌预测的现状:叙述性综述。

Current status of the prediction for radio-iodine refractory thyroid cancer: a narrative review.

机构信息

Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, Shanxi, China.

Department of Nuclear Medicine, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, Shanxi, China.

出版信息

Front Endocrinol (Lausanne). 2024 Oct 15;15:1433553. doi: 10.3389/fendo.2024.1433553. eCollection 2024.

Abstract

It is well established that patients with the most differentiated thyroid cancers have a good prognosis, whereas when the disease develops into radio-iodine refractory thyroid cancer (RAIR) their prognosis is poor and the 10-year survival rate is low. At present, the therapeutic methods for RAIR are limited and have low efficacy. As a consequence, several models have been developed for predicting RAIR. The aim of this review was to describe recent developments regarding the factors that influence and predict the occurrence of RAIR. Many variables including demographic characteristics, tumor clinicopathology, serology changes, disease characteristics, and PET/CT results have been shown to be independent factors that influence the development of RAIR. The cut-off value derived from multivariate prediction models therefore effectively predicts the onset of RAIR. However, the current models for predicting RAIR were obtained through retrospective studies, and the prospective prediction studies are needed in the future to confirm their validity.

摘要

众所周知,分化型甲状腺癌患者预后良好,而当疾病发展为放射性碘难治性甲状腺癌(RAIR)时,其预后较差,10 年生存率较低。目前,RAIR 的治疗方法有限,疗效不佳。因此,已经开发了几种预测 RAIR 的模型。本综述的目的是描述影响和预测 RAIR 发生的因素的最新进展。许多变量,包括人口统计学特征、肿瘤临床病理学、血清学变化、疾病特征和 PET/CT 结果,已被证明是影响 RAIR 发展的独立因素。因此,多变量预测模型得出的截止值可有效预测 RAIR 的发生。然而,目前预测 RAIR 的模型是通过回顾性研究获得的,未来需要前瞻性预测研究来验证其有效性。

相似文献

1
Current status of the prediction for radio-iodine refractory thyroid cancer: a narrative review.
Front Endocrinol (Lausanne). 2024 Oct 15;15:1433553. doi: 10.3389/fendo.2024.1433553. eCollection 2024.
2
Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
Ann Diagn Pathol. 2024 Apr;69:152243. doi: 10.1016/j.anndiagpath.2023.152243. Epub 2023 Dec 12.
3
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status.
J Endocrinol Invest. 2024 Jun;47(6):1573-1581. doi: 10.1007/s40618-024-02352-z. Epub 2024 Apr 5.
4
Radioactive iodine refractoriness in Middle Eastern differentiated thyroid cancer: clinical outcome and risk factor analysis.
Front Endocrinol (Lausanne). 2024 May 15;15:1326976. doi: 10.3389/fendo.2024.1326976. eCollection 2024.
6
Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer.
Front Endocrinol (Lausanne). 2024 Jan 19;14:1320044. doi: 10.3389/fendo.2023.1320044. eCollection 2023.
7
8
Clinical role of 18F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer.
Medicine (Baltimore). 2023 Jun 16;102(24):e33878. doi: 10.1097/MD.0000000000033878.
9
PET response assessment in apatinib-treated radioactive iodine-refractory thyroid cancer.
Endocr Relat Cancer. 2018 Jun;25(6):653-663. doi: 10.1530/ERC-18-0007. Epub 2018 Apr 4.

本文引用的文献

1
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status.
J Endocrinol Invest. 2024 Jun;47(6):1573-1581. doi: 10.1007/s40618-024-02352-z. Epub 2024 Apr 5.
2
Clinicopathological features of differentiated thyroid carcinoma as predictors of the effects of radioactive iodine therapy.
Ann Diagn Pathol. 2024 Apr;69:152243. doi: 10.1016/j.anndiagpath.2023.152243. Epub 2023 Dec 12.
5
[Analysis and prediction of thyroid cancer morbidity and mortality trends in China].
Zhonghua Liu Xing Bing Xue Za Zhi. 2023 Jun 10;44(6):917-923. doi: 10.3760/cma.j.cn112338-20221010-00869.
7
Blood Profiles in the Prediction of Radioiodine Refractory Papillary Thyroid Cancer: A Case-Control Study.
J Multidiscip Healthc. 2023 Feb 27;16:535-546. doi: 10.2147/JMDH.S403045. eCollection 2023.
8
A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer.
Front Endocrinol (Lausanne). 2023 Feb 10;14:1109439. doi: 10.3389/fendo.2023.1109439. eCollection 2023.
9
Utility of FDG PET at the Initial Radioiodine Therapy in Differentiated Thyroid Cancer.
Anticancer Res. 2023 Jan;43(1):183-190. doi: 10.21873/anticanres.16148.
10
Using 18F-FDG-PET/CT Metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers.
Diagnostics (Basel). 2022 Sep 30;12(10):2381. doi: 10.3390/diagnostics12102381.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验